PBAC's latest decision on Beclometasone with formoterol: Recommended with restriction (2022). Considered for Maintenance treatment of asthma in adults aged 18 years and older who are not adequately controlled with inhaled corticosteroids and 'as needed' inhaled rapid-acting beta2 agonist, or who are already adequately controlled on both ICS and long-acting beta2-agonists.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2022
Submissions
1
2022 → 2022
Eligible population
Adults aged 18 years and older with asthma not adequately controlled with inhaled corticosteroids and 'as needed' rapid-acting beta2 agonist, or already adequately controlled on both ICS and long-acting beta2-agonists